Trial intelligence / Profile preview

Zanubrutinib in Japanese real-world practice for Waldenstrom macroglobulinemia

jRCT1071260052Recruiting

Sponsor
BeOne Medicines
Start
Jul 2026
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Countries
1
01

Overview

Open-label, single-arm trial of zanubrutinib in Waldenström macroglobulinemia (WM), sponsored by BeOne Medicines. Primary endpoint: Response rate of very good partial response or better up to 12 months after treatment start. Started Jul 2026; status: recruiting.

02

Drugs

zanubrutinib
03

Conditions

Waldenström macroglobulinemia (WM)

Beyond the preview

Go deeper on jRCT1071260052.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on jRCT1071260052.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call